JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Guardant Health Inc

Închisă

SectorSănătate

89.17 1.4

Rezumat

Modificarea prețului

24h

Curent

Minim

85.56

Maxim

90.78

Indicatori cheie

By Trading Economics

Venit

-36M

-128M

Vânzări

16M

281M

EPS

-0.5

Marjă de profit

-45.684

Angajați

2,490

EBITDA

-37M

-119M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+46.73% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-1.7B

12B

Deschiderea anterioară

87.77

Închiderea anterioară

89.17

Sentimentul știrilor

By Acuity

50%

50%

186 / 348 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Guardant Health Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2026, 19:19 UTC

Achiziții, Fuziuni, Preluări

Intertek Group Rejects EQT's Revised Offer

24 apr. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Scoring the Cook Era -- Barrons.com

24 apr. 2026, 20:51 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:50 UTC

Market Talk
Evenimente importante

Financial Services Roundup: Market Talk

24 apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 apr. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:09 UTC

Câștiguri

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr. 2026, 19:48 UTC

Market Talk
Evenimente importante

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr. 2026, 19:22 UTC

Câștiguri

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr. 2026, 19:06 UTC

Câștiguri

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr. 2026, 18:30 UTC

Achiziții, Fuziuni, Preluări

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr. 2026, 18:28 UTC

Achiziții, Fuziuni, Preluări

Intertek Rejects Revised EQT Offer

24 apr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr. 2026, 17:42 UTC

Câștiguri

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr. 2026, 17:28 UTC

Câștiguri

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 apr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr. 2026, 17:09 UTC

Market Talk
Câștiguri

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr. 2026, 17:09 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 17:06 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr. 2026, 16:51 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr. 2026, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

24 apr. 2026, 16:20 UTC

Market Talk
Evenimente importante

Financial Services Roundup: Market Talk

24 apr. 2026, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

24 apr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparație

Modificare preț

Guardant Health Inc Așteptări

Obiectiv de preț

By TipRanks

46.73% sus

Prognoză pe 12 luni

Medie 128.93 USD  46.73%

Maxim 175 USD

Minim 86.72 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGuardant Health Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

18 ratings

17

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

38.86 / 47.41Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

186 / 348 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat